Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Prematu... (

HOME >> BIOLOGY >> TECHNOLOGY

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

Date:9/23/2008

- Premacure to Initiate Phase II Trial for IPLEX(TM) in Retinopathy of Prematurity -

RICHMOND, Va. and UPPSALA, Sweden, Sept. 23 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics (FOBs) and biopharmaceuticals, and Premacure AB, a biopharmaceutical company dedicated to the development of diagnosis and prevention of complications in neonates due to premature birth, today noted the presentation of clinical study results demonstrating that Insmed's IPLEX(TM) product, a complex of recombinant human insulin-like growth factor (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3), increased serum IGF-I levels into the normal range in significantly premature infants. Premacure is developing IPLEX(TM) as a potential treatment for Retinopathy of Prematurity (ROP) via a Material Transfer Agreement with Insmed.

These most recent study results were reported today at the European Society for Pediatric Endocrinology 47th annual meeting, Istanbul, Turkey, by Investigators from the Harvard Medical School, Boston MA, and the University of Gothenburg, The Karolinska Institute, Stockholm, Lund University, Sweden, in a poster entitled "Pharmacokinetic study of recombinant human (rh) insulin-like growth factor/rh IGFBP-3 complex administered to very low birth weight infants."

"The possibility of preventing ROP and other complications of prematurity by replicating the in utero environment after infants are born prematurely and lose the factors normally provided by the maternal environment is very exciting," said Lois Smith, Professor of Ophthalmology, Harvard Medical School, Children's Hospital Boston. "This work showing that it is now possible to raise the serum level of IGF-1 and IGFBP-3 to normal in utero levels in these fragile infants with IGF-1 / IGFBP-3 deficiency is a critical step in the development of interventions that prevent ROP. Since we have shown that low IGF-1 is associated with ROP, this of
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Insmed to Present at Biosimilars 2008 Conference
2. Insmed to Present at BioPharm Asia 2008 Conference
3. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
4. Insmed CEO to Present at Drug Discovery & Development Conference
5. Insmed to Host Second Quarter 2008 Conference Call
6. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
7. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
8. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
9. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
10. Insmed Announces First Quarter 2008 Financial Results
11. Insmed to Present at CBI Follow-On Biologics Conference

Post Your Comments:

Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Prematu...( - Premacure to Initiate Phase II ...)